CDK4/6 inhibitors in advanced breast cancer, what is beyond?

被引：4

作者：

Mohammed, Amrallah A. ^{[1
,2
]}

Rashied, Hanaa ^{[3
]}

Elsayed, Fifi Mostafa ^{[4
]}

机构：

[1] Zagazig Univ, Fac Med, Med Oncol Dept, 29 Saad Zaghloul, Zagazig 44519, Egypt

[2] King Salman Armed Forces Hosp, Tabuk City, Saudi Arabia

[3] El Mabra Hosp, Zagazig, Egypt

[4] Suez Canal Univ, Dept Fac Med, Clin Oncol & Nucl Med, Ismailia, Egypt

来源：

ONCOLOGY REVIEWS | 2019年 / 13卷 / 02期

关键词：

Breast cancer; CDK4/6; inhibitors; predictors of response and resistance; RIBOCICLIB PLUS LETROZOLE; KINASE; 4/6; INHIBITOR; 1ST-LINE TREATMENT; ENDOCRINE THERAPY; PALBOCICLIB; ABEMACICLIB; COMBINATION; RESISTANCE; FULVESTRANT; SUPPRESSION;

D O I：

10.4081/oncol.2019.416

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/61) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2-ABC, mechanisms of resistance, and promising future implementation.

引用

页码：125 / 133

页数：9

共 50 条

[1] CDK4/6 Inhibitors : Promising Opportunities beyond Breast Cancer
Lim, Joline S. J.
Turner, Nicholas C.
Yap, Timothy A.
CANCER DISCOVERY, 2016, 6 (07) : 697 - 699
[2] CDK4/6 inhibitors in breast cancer
Dukelow, Tim
Kishan, Divya
Khasraw, Mustafa
Murphy, Conleth G.
ANTI-CANCER DRUGS, 2015, 26 (08) : 797 - 806
[3] CDK4/6 Inhibitors for Advanced Hormone Receptor-Positive Breast Cancer, 2019 and Beyond
Layman, Rachel M.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (02): : 190 - 192
[4] Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer
Echavarria, Isabel
Jerez, Yolanda
Martin, Miguel
Lopez-Tarruella, Sara
BREAST CARE, 2017, 12 (05) : 296 - 302
[5] Update on CDK4/6 Inhibitors in Breast Cancer
Tolaney, Sara M.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (06) : 298 - 300
[6] The Role of CDK4/6 Inhibitors in Breast Cancer
Murphy, Conleth G.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (06)
[7] The Role of CDK4/6 Inhibitors in Breast Cancer
Conleth G. Murphy
Current Treatment Options in Oncology, 2019, 20
[8] CDK4/6 inhibitors in luminal breast cancer
Gnant, Michael
Steger, Guenther G.
Bartsch, Rupert
LANCET ONCOLOGY, 2015, 16 (01): : 2 - 3
[9] CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update
O'Sullivan, Ciara C.
EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (12) : 1657 - 1667
[10] Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors
Bakovic, Matea
Bago, Martina
Benic, Lucija
Krajinovic, Magdalena
Silovski, Tajana
Plavetic, Natalija Dedic
Turkovic, Lu
Sertic, Miranda
Hadziabdic, Maja Ortner
ACTA PHARMACEUTICA, 2023, 73 (04) : 633 - 654

← 1 2 3 4 5 →